A recent case study reported that a 72-year-old male lung adenocarcinoma patient with an EGFR deletion mutation initially responded to EGFR-TKI treatment but later developed acquired resistance against EGFR-TKI. The gene discussed is EGFR; the disease is lung adenocarcinoma.